UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Go back to UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis| (NYSE: UCB) | Delayed: 32.85 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.85 | 52 Week High | $ | |||
| Open | $32.85 | 52 Week Low | $ | |||
| Day High | $32.85 | P/E | N/A | |||
| Day Low | $32.85 | EPS | $ | |||
| Volume | 17 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 143.13 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.13 | 52 Week High | $46.25 | |||
| Open | $143.13 | 52 Week Low | $32.74 | |||
| Day High | $143.13 | P/E | N/A | |||
| Day Low | $143.13 | EPS | $0.00 | |||
| Volume | 315 | |||||
